Head-to-head · Cost-Efficiency Index
LillyDirect Foundayo vs Peptivo
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
LillyDirect Foundayo
Patients who want an FDA-approved, manufacturer-direct oral GLP-1 rather than a compounded injectable.
Visit LillyDirect FoundayoPeptivo
Shoppers who value verifiable named pharmacy and medical-leadership credentials, willing to complete an intake quiz to see final pricing.
Visit PeptivoThe verdict
LillyDirect Foundayo and Peptivo tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with LillyDirect Foundayo (ranked #196, a hair above #199) — Patients who want an FDA-approved, manufacturer-direct oral GLP-1 rather than a compounded injectable. But Peptivo is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs LillyDirect Foundayo.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | LillyDirect Foundayo | Peptivo |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | Not disclosed | $169/mo (compounded) |
| Tirzepatide / mo | Not disclosed | $249/mo (compounded) |
| Semaglutide / yr (modeled) | — | $2,028 |
| Tirzepatide / yr (modeled) | — | $2,988 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Yes |
| Rank here | #196 | #199 |
LillyDirect Foundayo
63/100Where the value is
- First-party Eli Lilly program -- highest possible manufacturer authenticity
- FDA-approved branded drug (orforglipron), not an unapproved compounded formulation
- Published self-pay starting price ($149) via savings card
The tradeoffs
- Not semaglutide or tirzepatide -- a different molecule (orforglipron), so not directly comparable on this list
- The $149 price is tied to a specific Savings Card program with its own terms, not an unconditional list price
Peptivo
63/100Where the value is
- Four named, verifiable compounding pharmacy partners across multiple states
- Named Chief Medical Innovation Officer (MD) and VP of Pharmacy Operations, plus a physician advisory board
- Ships to all 50 states
The tradeoffs
- Exact GLP-1 pricing gated behind an intake quiz, not shown as a static table
- Company's own sibling NAD+ products use a first-month-then-higher pricing structure, raising unconfirmed suspicion the GLP-1 pricing may work the same way
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.